Pharma BD Deal Intelligence
A win: Solvay's $1.7B acquisition of Fournier Pharma delivered on its rationale, turning fenofibrate (TriCor) into Solvay's largest pharma franchise at roughly $500M/year in North American royalties. The catch—Solvay's independent pharma ambitions lasted only five years before the whole division was sold to Abbott for $6.6B in 2010.
Fournier's fenofibrate franchise became Solvay's top pharma earner, but Solvay never got to keep it — the whole pharma unit was sold to Abbott just 5 years later
Full analysis, sources & comparables →Solvay signed an MoU with Fournier shareholders to acquire 100% for €1.3B cash plus up to €300M earn-out; combined R&D budget €370M pro forma.
Solvay agreed to buy Fournier for €1.3B in cash to integrate the global fenofibrate leader; deal would boost Solvay pharma revenues 34% and profits 54% pro…
Retrospective on how the Abbott/Fournier fenofibrate franchise used product-hopping reformulations (Tricor 145mg, Trilipix) to defer generic competition, a…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Solvay agrees to acquire Fournier Pharma for EUR 1.3B (~$1.7B) plus up to EUR 300M earn-out; gains fenofibrate franchise (TriCor).
Fournier's fenofibrate franchise became Solvay's top pharma earner, but Solvay never got to keep it — the whole pharma unit was sold to Abbott just 5 years later
Assessment window: 15yr post-close.
$779M TriCor 2004 global sales
Hypertriglyceridemia and mixed dyslipidemia are lipid disorders characterized by elevated triglycerides and altered cholesterol profiles, often co-occurring with diabetes, obesity, and metabolic syndrome. Severe forms (TG ≥500 mg/dL) carry pancreatitis risk; moderate elevations contribute to atherosclerotic cardiovascular disease.
In 2005, the lipid-modifying market was dominated by HMG-CoA reductase inhibitors (statins) — Lipitor (atorvastatin, Pfizer), Zocor (simvastatin, Merck), Crestor (rosuvastatin, AstraZeneca) — addressing LDL cholesterol. Fibrate-class agents targeted residual triglyceride and HDL risk: TriCor (fenofibrate, Abbott/Fournier) was the category leader at $779M in 2004 sales, competing against Lopid (gemfibrozil, Pfizer, generic) and niacin formulations (Niaspan, Kos/Abbott). Fournier's strategic value to Solvay rested on (1) the Abbott US co-promotion economics on TriCor, which had successfully evergreened through reformulation cycles to defer generic entry, (2) global fenofibrate franchise rights ex-US, and (3) a cardio-metabolic R&D platform synergistic with Solvay's hypertension, obesity, and heart failure programs. The deal positioned Solvay as the global fenofibrate leader and boosted pro forma pharma revenue 34%. The franchise later faced pressure from prescription omega-3s (Lovaza, Vascepa), generic fenofibrate post-2012, and the JUPITER/ACCORD-Lipid trials questioning fibrate cardiovascular benefit, ultimately contributing to Solvay's 2010 sale of pharma to Abbott.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Solvay S.A. / Fournier Pharma (this deal) | 2005 | $1.7B | 71 |
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
| Yamanouchi Pharmaceutical / Fujisawa Pharmaceutical Co. Ltd. | 2005 | — | 92 |
| Sankyo Co., Ltd. / Daiichi Pharmaceutical Co., Ltd. | 2005 | $8.0B | 92 |
| Cephalon Inc. / Salmedix, Inc. | 2005 | $160M | 89 |
| Roche Holding AG / GlycArt Biotechnology AG | 2005 | $182M | 80 |
| Reckitt Benckiser plc / Boots Healthcare International | 2005 | $3.4B | 78 |
← Browse all deals · How we score deals
More: 2005 deals